EMA Issues Guidance on Patient-Reported Outcomes in Oncology Trials

The European Medicines Agency is providing guidance on how drugmakers can best incorporate patient-reported outcomes in developing oncology studies.

The guidance details prospective study designs, methodologies, instruments and benefits.

Early in the development of an oncology study, companies should consider whether PRO data could be meaningful. As with any endpoint, there should be a clear justification for the inclusion of PROs, the timing of assessments and the selection of instruments.

The guidance suggests baseline patient self-assessments last 20 minutes and subsequent assessments take 10 to 15 minutes to limit the burden on patients.

Read the guidance here: www.fdanews.com/04-22-16-EMAGuideline.pdf. ― José Vasquez

$895 $695


Subscribe to International Pharmaceutical Regulatory Monitor and save $200 off the regular one-year price of $895 — plus receive a FREE CD copy of our webinar The 24 Elements You Need for a World-Class Quality Agreement — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides English-language texts of important, hard to obtain proposals, regulations, guidelines and other documents.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.